BriaCell Therapeutics Corp. (BCTXL)
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the development of novel immunotherapies to transform cancer care. It currently advancing its Bria-IMT™ targeted immunotherapy in combination with an immune check point inhibitor in a pivotal 1 Phase 3 study in metastatic breast cancer. The company was founded by Charles L. Wiseman and Isaac Benjamin Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
BriaCell Therapeutics Corp.
Trials need funding. See this company's dilution risk and cash position.
- Phase 3Recruiting
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
SV-BR-1-GM, Cyclophosphamide
Breast Cancer, Metastatic Breast Cancer +3
NCT06072612Enrollment404StartDec 2023Primary CompletionDec 2027est.CompletionJun 2028est. - Phase 1/2Completed
SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer
SV-BR-1-GM, Cyclophosphamide
Breastcancer, Breast Neoplasm
NCT03066947Enrollment24StartMay 2017Primary CompletionNov 2018CompletionNov 2018 - Phase 1/2Completed
Combination Study of SV-BR-1-GM With Retifanlimab
SV-BR-1-GM, Low dose cyclophosphamide
Breast Cancer, Breast Neoplasm +2
NCT03328026Enrollment36StartMar 2018Primary CompletionMar 2026CompletionMar 2026 - Phase 1/2Unknown status
A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer
BC1 cell line, Bria-OTS regimen and CPI (tislelizumab)
Breast Cancer, Breast Tumor +4
NCT06471673Enrollment18StartMay 2024Primary CompletionApr 2025est.CompletionOct 2025est.
| Drug / Therapy | Link | ||
|---|---|---|---|
| Phase 3 | Recruiting | SV-BR-1-GM, Cyclophosphamide | NCT06072612 |
| Phase 1/2 | Completed | SV-BR-1-GM, Cyclophosphamide | NCT03066947 |
| Phase 1/2 | Completed | SV-BR-1-GM, Low dose cyclophosphamide | NCT03328026 |
| Phase 1/2 | Unknown status | BC1 cell line, Bria-OTS regimen and CPI (tislelizumab) | NCT06471673 |